ReviewCytokine & growth factor reviews2020
A critical evaluation of glucocorticoids in the management of severe COVID-19.
Review in Cytokine & growth factor reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04610567 (Two Phases Clinical Trial to Evaluate Safety and Efficacy of Methotrexate Associated to LDL Like Nanoparticles), which is not on this map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Two Phases Clinical Trial to Evaluate Safety and Efficacy of Methotrexate Associated to LDL Like Nanoparticles (LDE-MTX) in the Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The role of methylprednisolone in severe COVID-19 patients: a meta-analysis.Frontiers in medicine · 2024Pooled it
- Effectiveness of corticosteroids to treat coronavirus disease 2019 symptoms: A meta-analysis.Medicina clinica · 2022Pooled it
- Epidemiological and Clinical Characteristics of COVID-19 in Children: A Systematic Review and Meta-Analysis.Frontiers in pediatrics · 2020Pooled it
- Dexamethasone disrupts intracellular pH homeostasis to delay coronavirus infectious bronchitis virus cell entry via sodium hydrogen exchanger 3 activation.Journal of virology · 2025Article
- The efficacy and safety of corticosteroids in treating severe COVID-19 patients: A meta-analysis with trial sequential analysis.Pakistan journal of medical sciences · 2025Review
- Comprehensive Management of Rhino-Orbito-Cerebral Mucormycosis Post-COVID-19: A Case Report.Clinical case reports · 2024Article
- Cytokine Storm in COVID-19: Insight into Pathological Mechanisms and Therapeutic Benefits of Chinese Herbal Medicines.Medicines (Basel, Switzerland) · 2024Review
- Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.Current stem cell research & therapy · 2024Review
- Genetic variability in the glucocorticoid pathway and treatment outcomes in hospitalized patients with COVID-19: a pilot study.Frontiers in pharmacology · 2024Article
- Utilizing Protein-Peptide Hybrid Microarray for Time-Resolved Diagnosis and Prognosis of COVID-19.Microorganisms · 2023Article
- Novel Risks of Unfavorable Corticosteroid Response in Patients with Mild-to-Moderate COVID-19 Identified Using Artificial Intelligence-Assisted Analysis of Chest Radiographs.Journal of clinical medicine · 2023Article
- Immunosuppressive dead cell as lung-targeting vehicle and cytokine absorption material for cytokine storm attenuation of pneumonia.Materials today. Bio · 2023Article
- Staging of COVID-19 disease; using selected laboratory profiles for prediction, prevention and management of severe SARS-CoV-2 infection in Africa-review.African health sciences · 2023Review
- Effectiveness of corticosteroids to treat coronavirus disease 2019 symptoms: A meta-analysis.Medicina clinica (English ed.) · 2022Article
- Pharmacological therapies and drug development targeting SARS-CoV-2 infection.Cytokine & growth factor reviews · 2022Review
- Histopathological, physiological and biochemical assessment of resveratrol nanocapsules efficacy in bleomycin-induced acute and chronic lung injury in rats.Drug delivery · 2022Article
- Nutritional parameters associated with prognosis in non-critically ill hospitalized COVID-19 patients: The NUTRI-COVID19 study.Clinical nutrition (Edinburgh, Scotland) · 2022Article
- Effects of Different Corticosteroid Doses in Elderly Unvaccinated Patients with Severe to Critical COVID-19.Life (Basel, Switzerland) · 2022Article
- Current Treatments for COVID-19: Application of Supercritical Fluids in the Manufacturing of Oral and Pulmonary Formulations.Pharmaceutics · 2022Review
- Managing Traumatic Brain Injury During the Coronavirus Disease 2019 Pandemic-A Case-Matched Controlled Analysis of Immediate Outcomes.World neurosurgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The viral infection by SARS-CoV-2 has irrevocably altered the life of the majority of human beings, challenging national health systems worldwide, and pushing researchers to rapidly find adequate preventive and treatment strategies. No therapies have been shown effective with the exception of dexamethasone, a glucocorticoid that was recently proved to be the first life-saving drug in this disease. Remarkably, around 20 % of infected people develop a severe form of COVID-19, giving rise to respiratory and multi-organ failures requiring subintensive and intensive care interventions. This phenomenon is due to an excessive immune response that damages pulmonary alveoli, leading to a cytokine and chemokine storm with systemic effects. Indeed glucocorticoids' role in regulating this immune response is controversial, and they have been used in clinical practice in a variety of countries, even without a previous clear consensus on their evidence-based benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.